Locoid Crelo skin emulsion 1mg/g 30g — Made in Italy — Free Delivery

Skin emulsion "Locoid Krelo" is used in conditions when there is a response to treatment with corticosteroids (eczema, dermatitis, psoriasis). Topical corticosteroids are generally not indicated for the treatment of psoriasis, but may be acceptable, with the exception of common plaque psoriasis, provided precautions are taken.

The active ingredient is hydrocortisone 17-butyrate (1 g of the emulsion contains 1 mg of hydrocortisone 17-butyrate).

Excipients: cetostearyl alcohol, macrogol cetostearyl ether, white soft paraffin, paraffin, borage oil, propylene glycol, butyl hydroxytoluene (E 321), propyl parahydroxybenzoate (E 216), butyl parahydroxybenzoate, purified acid, sodium citrate, lemon

Except in cases of treatment in combination with appropriate chemotherapeutic agents:

For cutaneous use.

Apply the preparation in a small amount with a thin even layer to the affected areas no more than 2 times a day.

This form of release of the preparation allows it to be used both for lesions that are accompanied by desquamation and weeping lesions.

The total course dose should not exceed 30-60 g of the preparation per week.

The same doses are used in adults and elderly patients, since there is no clinical evidence indicating that elderly patients need a special dosing regimen.

Data on the use of hydrocortisone butyrate in pregnant women are lacking or limited. The results of studies on laboratory animals indicate the reproductive toxicity of the preparation. Corticosteroids cross the placenta. With the systemic use of large doses of corticosteroids, the effect on the fetus or newborn child (fetal growth retardation, adrenocortical suppression) has been reported. Despite the small amount of information on the use of corticosteroids on the skin of pregnant women, given the limited systemic absorption of preparations in this group, it is possible to use corticosteroids of weak and moderate action (class 1 and class 2), such as hydrocortisone, for short periods of time and on limited skin areas ... The aforementioned effects cannot be ruled out with prolonged use or when applied to large areas of the skin. This can only be done with special indications.

Hydrocortisone butyrate / metabolites pass into breast milk, however, when using the preparation in therapeutic doses, exposure to newborns / breastfed infants is not expected. The preparation can be used by women during lactation only under conditions of short-term treatment and application to small areas of the skin. With long-term treatment or application to large areas of affected skin, breastfeeding should be discontinued.